Plant Comparison

Perforate St John’s-wort vs Mallow

A side-by-side comparison of two medicinal plants — every documented constituent, action, use, safety note and cited source, assembled automatically from the Omnia Sana database.

First plant
Second plant
Show:
Plant APerforate St John’s-wortHypericum perforatumHypericaceaeFull monograph →
Plant BMallowMalva sylvestrisMalvaceaeFull monograph →

At a glance

Perforate St John’s-wort and Mallow: they share 6 indicated uses (arthritis / joint pain, bruising, infection (general), …); 3 pharmacological actions in common.

Perforate St John’s-wortMallow
Constituents34
Pharmacological actions68
Indicated uses913
Safety notes22
Cited sources3113
Indicated uses
Only Perforate St John’s-wort
Cold & fluEczemaInsomnia / sleeplessness
Shared (6)
Arthritis / joint painBruisingInfection (general)Inflammation (general)Skin irritationWounds
Only Mallow
Back painCancer (anticancer research)ConstipationCoughHeadachePain (general)Sore throat
Pharmacological actions
Only Perforate St John’s-wort
AntiviralEmollient / skin-soothingSedative / sleep support
Shared (3)
Anti-inflammatoryAntioxidantVulnerary (wound healing)
Only Mallow
Analgesic (pain relief)Anticancer (preclinical)AntimicrobialDemulcent (soothing mucilage)Laxative

Evidence face-off — shared uses

ConditionPerforate St John’s-wortMallowVerdict
Arthritis / joint pain1/101/10Comparable evidence
Bruising1/101/10Comparable evidence
Infection (general)1/101/10Comparable evidence
Inflammation (general)1/102/10Comparable evidence
Skin irritation1/102/10Comparable evidence
Wounds1/105/10Stronger for Mallow

Evidence scores (1–10) are computed from the tier of each cited source. “Comparable” means the two scores are within one point. Follow a score to its detailed sources.

Key Constituents

Naphthodianthrones (hypericin, pseudohypericin)[4]

Red pigments historically used to standardise extracts; contribute to antiviral activity and are the compounds responsible for photosensitivity risk.

Phloroglucinols (hyperforin)[4]

Considered the principal compound behind the antidepressant activity and the main driver of the herb's potent CYP3A4/P-glycoprotein induction and drug-interaction profile.

Hyperforin
Flavonoids (hyperoside, quercetin, rutin)[4]

Antioxidant flavonoids contributing to overall activity.

FlavonoidsQuercetinRutin
Mucilage polysaccharides[11]

The high mucilage content gives the demulcent, soothing action.

PolysaccharidesMucilage
Anthocyanins (malvin) and flavonoids[11, 12, 13]

The blue-purple pigments and antioxidant constituents.

AnthocyaninsFlavonoids
Coumarins and other phenolic compounds[12, 13]

Phenolic constituents associated with antioxidant and reported antiproliferative (anticancer) activity in cell studies.

Phenolic compoundsCoumarins
Tannins[11]

Mildly astringent constituents.

Tannins

Pharmacological Actions

Anti-inflammatory[5, 15, 16]
Antioxidant[6, 15, 16]
Antiviral[15, 16]
Emollient / skin-soothing[15, 16]
Sedative / sleep support[1, 2, 4, 5, 9, 11, 12, 13, 14, 15, 16]
Vulnerary (wound healing)[4, 15, 16]
Analgesic (pain relief)[8, 12, 13]

Anti-inflammatory, analgesic and wound-healing (preclinical)

Anti-inflammatory[2, 3, 6, 7, 9, 10, 12, 13]

Anti-inflammatory, analgesic and wound-healing (preclinical)

Anticancer (preclinical)[1]
Antimicrobial[12, 13]

Antibacterial / antimicrobial (methanolic leaf extracts; the naphthoquinone Malvone A)

Antioxidant[1, 4, 5, 9, 12, 13]

Antioxidant (phenolic compounds and anthocyanins)

Demulcent (soothing mucilage)[2, 11]

Demulcent for irritation of the mouth or throat and associated dry cough (soothing mucilage); Mild laxative for occasional constipation (mucilage; traditional)

Laxative[11]

Mild laxative for occasional constipation (mucilage; traditional)

Vulnerary (wound healing)[8, 9, 12, 13]

Anti-inflammatory, analgesic and wound-healing (preclinical)

Traditional & Indicated Uses

Arthritis / joint pain[15, 16]Traditional · 1/10

inferred from anti-inflammatory action

Evidence: 1
Label: Arthritis / joint pain
Bruising[15, 16]Traditional · 1/10

inferred from vulnerary action

Evidence: 1
Label: Bruising
Cold & flu[15, 16]Traditional · 1/10

inferred from antiviral action

Evidence: 1
Label: Cold & flu
Eczema[15, 16]Traditional · 1/10

inferred from emollient action

Evidence: 1
Label: Eczema
Infection (general)[15, 16]Traditional · 1/10

inferred from antiviral action

Evidence: 1
Label: Infection (general)
Inflammation (general)[15, 16]Traditional · 1/10

inferred from anti-inflammatory action

Evidence: 1
Label: Inflammation (general)
Insomnia / sleeplessness[15, 16]Traditional · 1/10

inferred from sedative action

Evidence: 1
Label: Insomnia / sleeplessness
Skin irritation[15, 16]Traditional · 1/10

inferred from anti-inflammatory action

Evidence: 1
Label: Skin irritation
Wounds[15, 16]Traditional · 1/10

inferred from vulnerary action

Evidence: 1
Label: Wounds
Arthritis / joint pain[12, 13]Traditional · 1/10

inferred from anti-inflammatory action

Evidence: 1
Label: Arthritis / joint pain
Back pain[12, 13]Traditional · 1/10

inferred from analgesic action

Evidence: 1
Label: Back pain
Bruising[12, 13]Traditional · 1/10

inferred from vulnerary action

Evidence: 1
Label: Bruising
Cancer (anticancer research)[1]Good · 7/10

inferred from anticancer action

Evidence: 7
Label: Cancer (anticancer research)
Constipation[11]Traditional · 1/10

Mild laxative for occasional constipation (mucilage; traditional)

Evidence: 1
Label: Constipation
Cough[11]Traditional · 1/10

Demulcent for irritation of the mouth or throat and associated dry cough (soothing mucilage)

Evidence: 1
Label: Cough
Headache[12, 13]Traditional · 1/10

inferred from analgesic action

Evidence: 1
Label: Headache
Infection (general)[12, 13]Traditional · 1/10

inferred from antimicrobial action

Evidence: 1
Label: Infection (general)
Inflammation (general)[3, 6, 10, 12, 13]Traditional · 2/10

inferred from anti-inflammatory action

Evidence: 2
Label: Inflammation (general)
Pain (general)[8, 12, 13]Moderate · 5/10

inferred from analgesic action

Evidence: 5
Label: Pain (general)
Skin irritation[7, 11]Traditional · 2/10

Soothes irritated and inflamed skin and mucous membranes

Evidence: 2
Label: Skin irritation
Sore throat[11]Traditional · 1/10
Evidence: 1
Label: Sore throat
Wounds[8, 12, 13]Moderate · 5/10

inferred from antimicrobial action

Evidence: 5
Label: Wounds

Safety, Cautions & Contraindications

Safety note[15, 16]Caution

Significant drug interactions: strongly induces CYP3A4 and P-glycoprotein, reducing plasma levels of many drugs including oral contraceptives, antiretrovirals, cyclosporine, warfarin, and digoxin. May cause photosensitivity (fair-skinned individuals). Do not combine with SSRIs, SNRIs, or MAOIs (serotonin syndrome risk). Avoid in bipolar disorder.

Safety note[15, 16, 17]Caution

Duke (2002) rates St. John's wort as ++ (raised from earlier editions) and notes antidepressant, antiviral, antibacterial, and wound-healing activities at experimental and clinical levels. Hypericin and hyperforin are identified as key active constituents. Clinical evidence (score 2) confirms antidepressant efficacy in mild-to-moderate depression, and WHO/Commission E provide approval for this indication. Dose: 300 mg standardized extract (0.3% hypericin, 3–5% hyperforin) three times daily. Duke emphasizes the critical drug interaction: St. John's wort is a potent CYP3A4 inducer and can significantly reduce blood levels of many medications including oral contraceptives, cyclosporine, antiretrovirals, and warfarin. Avoid combined use with SSRIs (serotonin syndrome risk) and pharmaceutical antidepressants (Duke, 2002).

Safety note[11]Info

Generally very well tolerated. Irritation of the mouth/throat or a cough that persists beyond about a week, or is accompanied by fever or breathlessness, needs medical assessment.

Safety note[11]Caution

Use in pregnancy and breastfeeding is not recommended in the absence of adequate data.

External Ids

Gbif: 3189486
Powo: urn:lsid:ipni.org:names:433719-1
Wikidata: Q158289
Gbif: 3152374
Wikidata: Q156835

Botanical Description

Erect, branching perennial herb with paired, oval leaves dotted with tiny translucent oil glands that look like pinpricks when held to the light (giving the species name 'perforatum'). Bright yellow, five-petalled flowers with numerous stamens and black dots along the petal edges are borne in flat-topped clusters, and release a reddish pigment when crushed.[4]

Height: 30-90 cm
Habit: Erect, branching perennial herb
Leaves: Paired, oval, dotted with tiny translucent oil glands
Flowers: Bright yellow, five-petalled, with numerous stamens and black-dotted petal edges, in flat-topped clusters
Stem: Erect, branching, with two raised longitudinal ridges
Root: Woody rootstock with spreading rhizomes
Fruit: Small, three-valved capsule
Flowering Period: June-September (traditionally around St John's Day, 24 June)

Biennial or short-lived perennial herb, 30-120 cm tall, with erect or sprawling, branched, often reddish stems. Leaves are alternate, long-stalked and palmately lobed with 5-7 shallow rounded lobes and toothed margins. Flowers are pink-purple with darker veining, with five notch-tipped petals borne in small axillary clusters. The fruit is a flattened, disc-shaped schizocarp ('cheese') that splits into a ring of small single-seeded nutlets.[2]

Height: 30-120 cm
Habit: Erect to sprawling biennial/perennial herb
Leaves: Alternate, long-stalked, palmately 5-7-lobed with toothed margins
Flowers: Pink-purple with darker veins, five notched petals, in small axillary clusters
Stem: Erect or sprawling, branched, often reddish
Root: Taproot
Fruit: Flattened disc-shaped schizocarp ('cheese') of small nutlets
Flowering Period: June-September

Habitat

Grows in grassland, roadsides, woodland clearings and waste ground on well-drained soils; native to Europe, Western Asia and North Africa and widely naturalised elsewhere, including North America and Australia.[4]

Common on roadsides, waste ground, hedgebanks and field margins across Europe, North Africa and temperate Asia, and widely naturalised elsewhere; tolerates a wide range of soils, favouring sunny, disturbed, nitrogen-rich sites.[2]

Harvesting

The flowering tops (flower and upper leaf) are cut in summer as the flowers open, around the traditional St John's Day period, and dried quickly in a warm, shaded, airy place to preserve the hypericin and hyperforin content.[4]

Parts: Flower, Leaf
Season: Summer, at flowering

Leaves and flowers are gathered during the flowering period (summer) and dried quickly out of direct sun to preserve their mucilage content; fresh material can also be used directly for infusions or poultices.[11]

Parts: Leaf, Flower
Season: Summer, during flowering

Traditional Uses

St John's wort has a centuries-long European folk reputation as a wound-healing and nerve tonic herb, traditionally used for mild wounds, burns and nerve pain and to lift low mood; this traditional mood-supporting use is now one of the most extensively clinically studied applications of any herbal medicine, with standardised extracts shown comparable to conventional antidepressants for mild-to-moderate depression.[1, 4]

Mallow leaf and flower have a long ethnobotanical history across Europe as a demulcent for irritated mucous membranes - soothing coughs, sore throat and mouth irritation - and for occasional constipation and skin irritation, reflecting the mucilage-rich leaf and flower. Modern phytochemical and pharmacological work confirms antioxidant, anti-inflammatory, antimicrobial and wound-healing activity of its extracts.[2, 11]

Preparations

Standardised extract[1]

Flowering-top extract standardised to hypericin and/or hyperforin content, taken as tablets or capsules; the best-studied clinical form for mood support.

Infusion (hot)[11]

Dried leaf and/or flower steeped in hot water as a traditional soothing tea for cough, sore throat and mild digestive irritation.

Poultice/compress[7]

Crushed fresh or softened dried leaf applied externally to soothe irritated or inflamed skin.

Dosage

Standardised extract[1]

Clinical trials for mild-to-moderate depression commonly use around 300 mg of standardised extract three times daily (900 mg/day total); given extensive drug interactions, use should be discussed with a healthcare provider, especially alongside other medicines. Educational reference only, not a prescription.

Infusion[11]

EMA herbal-monograph guidance suggests roughly 1.5-2 g of dried leaf or flower per cup, taken as an infusion up to 3 times daily. Educational reference only, not a prescription.

Drug Class Interactions

Safety note[18, 19, 20, 21]Avoid
Drug Class: antidepressants-serotonergic
Mechanism: St John's wort raises serotonin activity; combined with SSRIs, SNRIs or MAOIs it can trigger serotonin syndrome (agitation, tremor, sweating, rapid heartbeat). Reviews of clinical reports document serotonin syndrome and lethargy when it is combined with serotonin-reuptake inhibitors.
Reviewed By: Omnia Sana (owner-authorized)
Reviewed Date: 2026-07-03
Safety note[18, 19, 22]Avoid
Drug Class: antiretrovirals
Mechanism: Potent CYP3A4 and P-glycoprotein induction lowers antiretroviral levels (indinavir exposure fell ~57%), risking loss of viral control and drug resistance.
Reviewed By: Omnia Sana (owner-authorized)
Reviewed Date: 2026-07-03
Safety note[18, 19, 23]Avoid
Drug Class: immunosuppressants
Mechanism: Enzyme and transporter induction reduces ciclosporin and tacrolimus levels; reported to cause subtherapeutic concentrations and transplant rejection.
Reviewed By: Omnia Sana (owner-authorized)
Reviewed Date: 2026-07-03
Safety note[18, 24, 25, 26]Avoid
Drug Class: hormonal-therapies
Mechanism: Increased metabolism of ethinylestradiol and progestins reduces contraceptive exposure, causing breakthrough bleeding, ovulation and unplanned pregnancy. Randomised and controlled trials in women confirmed more breakthrough bleeding, reduced progestin levels and evidence of ovulation when St John's wort was added to the pill.
Reviewed By: Omnia Sana (owner-authorized)
Reviewed Date: 2026-07-03
Safety note[18, 19, 21]Caution
Drug Class: anticoagulants-antiplatelets
Mechanism: CYP induction increases warfarin clearance and can lower INR, reducing the anticoagulant effect; close monitoring is needed.
Reviewed By: Omnia Sana (owner-authorized)
Reviewed Date: 2026-07-03
Safety note[18, 27]Caution
Drug Class: cardiac-glycosides
Mechanism: P-glycoprotein induction lowers digoxin levels (AUC fell ~25% over ten days), which may reduce its effect.
Reviewed By: Omnia Sana (owner-authorized)
Reviewed Date: 2026-07-03
Safety note[18, 19, 21]Caution
Drug Class: statins
Mechanism: CYP3A4 induction lowers levels of simvastatin and atorvastatin, potentially weakening their cholesterol-lowering effect.
Reviewed By: Omnia Sana (owner-authorized)
Reviewed Date: 2026-07-03
Safety note[18, 19, 21]Caution
Drug Class: cyp3a4-substrates
Mechanism: As a broad CYP3A4 and P-glycoprotein inducer, St John's wort can lower levels of many medicines cleared by this pathway; check each medication individually.
Reviewed By: Omnia Sana (owner-authorized)
Reviewed Date: 2026-07-03
Safety note[20, 28, 29]Avoid
Drug Class: chemotherapy-agents
Mechanism: St John's wort strongly induces CYP3A4 and P-glycoprotein, speeding the breakdown and removal of several cancer medicines. In patients it cut the active form of irinotecan (SN-38) by about 42% and reduced imatinib exposure by roughly a third - enough to weaken treatment and risk drug resistance. Do not take St John's wort during chemotherapy.
Reviewed By: Omnia Sana (owner-authorized)
Reviewed Date: 2026-07-03

Not documented

References

REF-0842, REF-0843, REF-0844, REF-1789, REF-1790, REF-1791, REF-1792, REF-1793, REF-1794, REF-1795, REF-1796, REF-1797, REF-1798, REF-1799
REF-1183, REF-1184, REF-1185, REF-1186, REF-1187, REF-1188, REF-1189, REF-1190, REF-1191, REF-1192

Pairings

St John's wort raises serotonin activity and can cause serotonin syndrome when combined with other serotonin-boosting agents; pairing it with another mood-active, serotonergic herb such as saffron may add to this risk.[30]

Partner Id: crocus-sativus
Type: caution
Reviewed By: Omnia Sana (owner-authorized)
Reviewed Date: 2026-07-03

St John's wort is a strong enzyme inducer and increases serotonin activity; combining it with another antidepressant-type herb such as rhodiola may add to serotonergic effects and unpredictably change how each is handled by the body.[30]

Partner Id: rhodiola-rosea
Type: caution
Reviewed By: Omnia Sana (owner-authorized)
Reviewed Date: 2026-07-03

St John's wort speeds up the breakdown of many substances and also raises serotonin activity; pairing it with a sedative herb such as valerian may add to drowsiness and can unpredictably change how each is handled by the body.[30, 31]

Partner Id: valeriana-officinalis
Type: caution
Reviewed By: Omnia Sana (owner-authorized)
Reviewed Date: 2026-07-03

St John's wort is a strong enzyme inducer and kava is a liver-metabolised sedative; combining them may add to central-nervous-system effects and alter how kava is processed, so combined use warrants caution.[30, 31]

Partner Id: piper-methysticum
Type: caution
Reviewed By: Omnia Sana (owner-authorized)
Reviewed Date: 2026-07-03

Not documented

Lookalikes Review

Outcome: none-known
Reviewed By: Omnia Sana (owner-authorized)
Reviewed Date: 2026-07-07
Outcome: none-known
Reviewed By: Omnia Sana (owner-authorized)
Reviewed Date: 2026-07-07

References & Sources

  1. Ng, Q.X., Venkatanarayanan, N. and Ho, C.Y.X (2017) 'Clinical use of Hypericum perforatum (St John's wort) in depression: A meta-analysis', Journal of Affective Disorders, 210, pp. 211-221. doi:10.1016/j.jad.2016.12.048 Meta-analysis / review
    https://doi.org/10.1016/j.jad.2016.12.048
  2. Kholghi, G., Arjmandi-Rad, S., Zarrindast, M.R. and Vaseghi, S (2022) 'St. John's wort (Hypericum perforatum) and depression: what happens to the neurotransmitter systems?', Naunyn-Schmiedeberg's Archives of Pharmacology, 395(6), pp. 629-642. doi:10.1007/s00210-022-02229-z Traditional / reference
    https://doi.org/10.1007/s00210-022-02229-z
  3. Fugh-Berman, A (2000) 'Herb-drug interactions', Lancet, 355(9198), pp. 134-138. doi:10.1016/S0140-6736(99)06457-0 Traditional / reference
    https://doi.org/10.1016/S0140-6736(99)06457-0
  4. Nobakht, S.Z., Akaberi, M., Mohammadpour, A.H., Tafazoli Moghadam, A. and Emami, S.A (2022) 'Hypericum perforatum: Traditional uses, clinical trials, and drug interactions', Iranian Journal of Basic Medical Sciences, 25(9), pp. 1045-1058. doi:10.22038/IJBMS.2022.65112.14338 Meta-analysis / review
    https://doi.org/10.22038/IJBMS.2022.65112.14338
  5. Jiang, Z., Wang, F., Zhao, Y., Lu, L., Jiang, X., Huang, T., Lin, Y., Guo, L., Weng, Z. and Liu, E (2024) 'Hypericum perforatum L. attenuates depression by regulating Akkermansia muciniphila, tryptophan metabolism and NFkB-NLRP2-Caspase1-IL1beta pathway', Phytomedicine, 132, pp. 155847. doi:10.1016/j.phymed.2024.155847 Preclinical
    https://doi.org/10.1016/j.phymed.2024.155847
  6. Oliveira, A.I., Pinho, C., Sarmento, B. and Dias, A.C.P (2016) 'Neuroprotective Activity of Hypericum perforatum and Its Major Components', Frontiers in Plant Science, 7, pp. 1004. doi:10.3389/fpls.2016.01004 Meta-analysis / review
    https://doi.org/10.3389/fpls.2016.01004
  7. Russo, E., Scicchitano, F., Whalley, B.J., Mazzitello, C., Ciriaco, M., Esposito, S., Patane, M., Upton, R., Pugliese, M., Chimirri, S., Mammi, M., Palleria, C. and De Sarro, G (2013) 'Hypericum perforatum: pharmacokinetic, mechanism of action, tolerability, and clinical drug-drug interactions', Phytotherapy Research, 28(5), pp. 643-655. doi:10.1002/ptr.5050 Meta-analysis / review
    https://doi.org/10.1002/ptr.5050
  8. Saddiqe, Z., Naeem, I. and Maimoona, A (2010) 'A review of the antibacterial activity of Hypericum perforatum L', Journal of Ethnopharmacology, 131(3), pp. 511-521. doi:10.1016/j.jep.2010.07.034 Meta-analysis / review
    https://doi.org/10.1016/j.jep.2010.07.034
  9. Mennini, T. and Gobbi, M (2004) 'The antidepressant mechanism of Hypericum perforatum', Life Sciences, 75(9), pp. 1021-1027. doi:10.1016/j.lfs.2004.04.005 Meta-analysis / review
    https://doi.org/10.1016/j.lfs.2004.04.005
  10. Liu, Y., Jiang, Y., Huang, R., Yang, J., Xiao, B. and Dong, J (2013) 'Hypericum perforatum L. preparations for menopause: a meta-analysis of efficacy and safety', Climacteric, 17(4), pp. 325-335. doi:10.3109/13697137.2013.861814 Meta-analysis / review
    https://doi.org/10.3109/13697137.2013.861814
  11. Wurglics, M. and Schubert-Zsilavecz, M (2006) 'Hypericum perforatum: a 'modern' herbal antidepressant: pharmacokinetics of active ingredients', Clinical Pharmacokinetics, 45(5), pp. 449-468. doi:10.2165/00003088-200645050-00002 Meta-analysis / review
    https://doi.org/10.2165/00003088-200645050-00002
  12. Kasper, S (2001) 'Hypericum perforatum - a review of clinical studies', Pharmacopsychiatry, 34(Suppl 1), pp. S51-S55. doi:10.1055/s-2001-15467 Meta-analysis / review
    https://doi.org/10.1055/s-2001-15467
  13. Nathan, P (1999) 'The experimental and clinical pharmacology of St John's Wort (Hypericum perforatum L.)', Molecular Psychiatry, 4(4), pp. 333-338. doi:10.1038/sj.mp.4000557 Meta-analysis / review
    https://doi.org/10.1038/sj.mp.4000557
  14. Verotta, L (2003) 'Hypericum perforatum, a source of neuroactive lead structures', Current Topics in Medicinal Chemistry, 3(2), pp. 187-201. doi:10.2174/1568026033392589 Meta-analysis / review
    https://doi.org/10.2174/1568026033392589
  15. Linde, K. et al (2008) 'St John'. Traditional / reference
    https://scholar.google.com/scholar?q=St%20John
  16. Natural Standard (2013) 'Hypericum perforatum (St'. Traditional / reference
    https://scholar.google.com/scholar?q=Hypericum%20perforatum%20%28St
  17. Duke, J.A (2002) 'Handbook of Medicinal Herbs, Second Edition'. Traditional / reference
    https://scholar.google.com/scholar?q=Handbook%20of%20Medicinal%20Herbs%2C%20Second%20Edition
  18. Zhou, S., Chan, E., Pan, S.Q., Huang, M. and Lee, E.J.D (2004) 'Pharmacokinetic interactions of drugs with St John's wort', Journal of Psychopharmacology, 18(2), pp. 262-276. doi:10.1177/0269881104042632 Meta-analysis / review
    https://doi.org/10.1177/0269881104042632
  19. Izzo, A.A. and Ernst, E (2009) 'Interactions between herbal medicines and prescribed drugs: an updated systematic review', Drugs, 69(13), pp. 1777-1798. doi:10.2165/11317010-000000000-00000 Meta-analysis / review
    https://doi.org/10.2165/11317010-000000000-00000
  20. Borrelli, F. and Izzo, A.A (2009) 'Herb-drug interactions with St John's wort (Hypericum perforatum): an update on clinical observations', The AAPS Journal, 11(4), pp. 710-727. doi:10.1208/s12248-009-9146-8 Meta-analysis / review
    https://doi.org/10.1208/s12248-009-9146-8
  21. Nicolussi, S., Drewe, J., Butterweck, V. and Meyer zu Schwabedissen, H.E (2020) 'Clinical relevance of St. John's wort drug interactions revisited', British Journal of Pharmacology, 177(6), pp. 1212-1226. doi:10.1111/bph.14936 Meta-analysis / review
    https://doi.org/10.1111/bph.14936
  22. Piscitelli, S.C., Burstein, A.H., Chaitt, D., Alfaro, R.M. and Falloon, J (2000) 'Indinavir concentrations and St John's wort', Lancet, 355(9203), pp. 547-548. doi:10.1016/S0140-6736(99)05712-8 Clinical study
    https://doi.org/10.1016/S0140-6736(99)05712-8
  23. Barone, G.W., Gurley, B.J., Ketel, B.L., Lightfoot, M.L. and Abul-Ezz, S.R (2000) 'Drug interaction between St. John's wort and cyclosporine', Annals of Pharmacotherapy, 34(9), pp. 1013-1016. doi:10.1345/aph.10088 Clinical study
    https://doi.org/10.1345/aph.10088
  24. Murphy, P.A., Kern, S.E., Stanczyk, F.Z. and Westhoff, C.L (2005) 'Interaction of St. John's Wort with oral contraceptives: effects on the pharmacokinetics of norethindrone and ethinyl estradiol, ovarian activity and breakthrough bleeding', Contraception, 71(6), pp. 402-408. doi:10.1016/j.contraception.2004.11.004 Clinical study
    https://doi.org/10.1016/j.contraception.2004.11.004
  25. Murphy, P.A., Kern, S.E., Stanczyk, F.Z. and Westhoff, C.L (2005) 'Interaction of St. John's Wort with oral contraceptives: effects on the pharmacokinetics of norethindrone and ethinyl estradiol, ovarian activity and breakthrough bleeding', Contraception, 71(6), pp. 402-408. doi:10.1016/j.contraception.2004.11.004 Clinical study
    https://doi.org/10.1016/j.contraception.2004.11.004
  26. Pfrunder, A., Schiesser, M., Gerber, S., Haschke, M., Bitzer, J. and Drewe, J (2003) 'Interaction of St John's wort with low-dose oral contraceptive therapy: a randomized controlled trial', British Journal of Clinical Pharmacology, 56(6), pp. 683-690. doi:10.1046/j.1365-2125.2003.02005.x Randomized trial
    https://doi.org/10.1046/j.1365-2125.2003.02005.x
  27. Johne, A., Brockmoller, J., Bauer, S., Maurer, A., Langheinrich, M. and Roots, I (1999) 'Pharmacokinetic interaction of digoxin with an herbal extract from St John's wort (Hypericum perforatum)', Clinical Pharmacology and Therapeutics, 66(4), pp. 338-345. doi:10.1053/cp.1999.v66.a101944 Clinical study
    https://doi.org/10.1053/cp.1999.v66.a101944
  28. Mathijssen, R.H.J., Verweij, J., de Bruijn, P., Loos, W.J. and Sparreboom, A (2002) 'Effects of St. John's wort on irinotecan metabolism', Journal of the National Cancer Institute, 94(16), pp. 1247-1249. doi:10.1093/jnci/94.16.1247 Randomized trial
    https://doi.org/10.1093/jnci/94.16.1247
  29. Smith, P., Bullock, J.M., Booker, B.M., Haas, C.E., Berenson, C.S. and Jusko, W.J (2004) 'The influence of St. John's wort on the pharmacokinetics and protein binding of imatinib mesylate', Pharmacotherapy, 24(11), pp. 1508-1514. doi:10.1592/phco.24.16.1508.50958 Clinical study
    https://doi.org/10.1592/phco.24.16.1508.50958
  30. Izzo, A.A (2004) 'Drug interactions with St. John's Wort (Hypericum perforatum): a review of the clinical evidence', International Journal of Clinical Pharmacology and Therapeutics, 42(3), pp. 139-148. doi:10.5414/cpp42139 Meta-analysis / review
    https://doi.org/10.5414/cpp42139
  31. Caus, M.N., Lupoae, M. and Chitescu, C.L (2026) 'Efficacy and Safety of Herbal Supplements with Anxiolytic, Antidepressant, and Sedative Action: A Review of Clinical Data and Toxicological Risks', Pharmaceuticals, 19(3), pp. 399. doi:10.3390/ph19030399 Meta-analysis / review
    https://doi.org/10.3390/ph19030399
  1. Mousavi, S.M., Hashemi, S.A., Behbudi, G., Mazraedoost, S. and others (2021) 'A Review on Health Benefits of Malva sylvestris L. Nutritional Compounds for Metabolites, Antioxidants, and Anti-Inflammatory, Anticancer, and Antimicrobial Applications', Evidence-Based Complementary and Alternative Medicine, 2021, pp. 5548404. doi:10.1155/2021/5548404 Meta-analysis / review
    https://doi.org/10.1155/2021/5548404
  2. Gasparetto, J.C., Martins, C.A., Hayashi, S.S., Otuky, M.F. and others (2012) 'Ethnobotanical and scientific aspects of Malva sylvestris L.: a millennial herbal medicine', Journal of Pharmacy and Pharmacology, 64(2), pp. 172-189. doi:10.1111/j.2042-7158.2011.01383.x Meta-analysis / review
    https://doi.org/10.1111/j.2042-7158.2011.01383.x
  3. Wu, Y., Qiu, A., Yang, Z., Wu, J. and others (2019) 'Malva sylvestris extract alleviates the astrogliosis and inflammatory stress in LPS-induced depression mice', Journal of Neuroimmunology, 336, pp. 577029. doi:10.1016/j.jneuroim.2019.577029 Preclinical
    https://doi.org/10.1016/j.jneuroim.2019.577029
  4. Ben Saad, A., Rjeibi, I., Brahmi, D., Smida, A. and others (2016) 'Malva sylvestris extract protects upon lithium carbonate-induced kidney damages in male rat', Biomedicine & Pharmacotherapy, 84, pp. 1099-1107. doi:10.1016/j.biopha.2016.10.026 Preclinical
    https://doi.org/10.1016/j.biopha.2016.10.026
  5. Zuo, H., Li, Y., Cui, Y. and An, Y (2017) 'Cardioprotective effect of Malva sylvestris L. in myocardial ischemic/reperfused rats', Biomedicine & Pharmacotherapy, 95, pp. 679-684. doi:10.1016/j.biopha.2017.08.111 Preclinical
    https://doi.org/10.1016/j.biopha.2017.08.111
  6. Benso, B., Rosalen, P.L., Alencar, S.M. and Murata, R.M (2015) 'Malva sylvestris Inhibits Inflammatory Response in Oral Human Cells. An In Vitro Infection Model', PLoS One, 10(10), pp. e0140331. doi:10.1371/journal.pone.0140331 Preclinical
    https://doi.org/10.1371/journal.pone.0140331
  7. Prudente, A.S., Sponchiado, G., Mendes, D.A.G.B., Soley, B.S. and others (2017) 'Pre-clinical efficacy assessment of Malva sylvestris on chronic skin inflammation', Biomedicine & Pharmacotherapy, 93, pp. 852-860. doi:10.1016/j.biopha.2017.06.083 Preclinical
    https://doi.org/10.1016/j.biopha.2017.06.083
  8. Mohaghegh, Z., Golfakhrabadi, F., Faal Siahkal, S., Dastoorpoor, M. and others (2022) 'The Effect of Malva sylvestris Cream on Episiotomy Pain and Healing: A Randomized Controlled Clinical Trial', International Journal of Community Based Nursing and Midwifery, 10(4), pp. 248-258. doi:10.30476/IJCBNM.2022.95772.2082 Randomized trial
    https://doi.org/10.30476/IJCBNM.2022.95772.2082
  9. Areesanan, A., Nicolay, S., Keller, M., Zimmermann-Klemd, A.M. and others (2023) 'Potential benefits of Malva sylvestris in dry-eye disease pathology in vitro based on antioxidant, wound-healing and anti-inflammatory properties', Biomedicine & Pharmacotherapy, 168, pp. 115782. doi:10.1016/j.biopha.2023.115782 Preclinical
    https://doi.org/10.1016/j.biopha.2023.115782
  10. Martins, C.A., Weffort-Santos, A.M., Gasparetto, J.C., Trindade, A.C. and others (2014) 'Malva sylvestris L. extract suppresses desferrioxamine-induced PGE2 and PGD2 release in differentiated U937 cells', Biomedical Chromatography, 28(7), pp. 986-993. doi:10.1002/bmc.3106 Preclinical
    https://doi.org/10.1002/bmc.3106
  11. European Medicines Agency (HMPC) (n.d.) 'European Union herbal monograph on Malva sylvestris L., folium and flos (Malvae folium / Malvae sylvestris flos)'. Available at: https://www.ema.europa.eu/en/medicines/herbal/malvae-folium Traditional / reference
    https://www.ema.europa.eu/en/medicines/herbal/malvae-folium
  12. Paul, Z.A. and Malla, A.T. and Dar, M.A. and Masoodi, M.H (2024) 'Phytochemistry and Pharmacological Activity of Malva sylvestris L.: A Detailed Insight', Combinatorial Chemistry & High Throughput Screening, 27(16), pp. 2309--2322. doi:10.2174/0113862073269336231009110313 Traditional / reference
    https://doi.org/10.2174/0113862073269336231009110313
  13. Batiha, G.E. and Tene, S.T. and Teibo, J.O. and Shaheen, H.M. and Oluwatoba, O.S. and Teibo, T.K.A. and Al-Kuraishy, H.M. and Al-Garbee, A.I. and Alexiou, A. and Papadakis, M (2022) 'The phytochemical profiling, pharmacological activities, and safety of Malva sylvestris: a review', Naunyn-Schmiedeberg's Archives of Pharmacology, 396(3), pp. 421--440. doi:10.1007/s00210-022-02329-w Traditional / reference
    https://doi.org/10.1007/s00210-022-02329-w

Generated automatically from the Omnia Sana plant database and its cited sources. For educational purposes only — not medical advice. Always consult a qualified practitioner before using medicinal plants.